---

Coronavirus: Immunosuppression

Answer

Those who are at higher risk of serious outcomes from COVID-19, including the immunosuppressed and/or immunocompromised, remain a priority for the Government and as such are offered enhanced protections and interventions such as treatments, vaccines, and public health advice. The Government recently updated the online-only COVID-19: guidance for people whose immune system means they are at higher risk on 30 January 2023.

In rare cases where people may have a medical contraindication to currently available COVID-19 vaccines, individuals are able to access services such as a referral to an allergist or other appropriate specialist, to consider administration of the implicated mRNA vaccine under medical supervision in a suitable environment. When mRNA vaccines are not considered clinically suitable, the Novavax COVID-19 vaccine Nuvaxovid, a protein subunit vaccine, may be used as an alternative for people who are contraindicated against and cannot have any alternative clinically suitable United Kingdom-approved COVID-19 vaccine. The Government continues to be guided by the independent Joint Committee on Vaccination and Immunisation on the COVID-19 vaccination programme.

Immunosuppressed individuals are also a priority cohort for research into therapeutic and prophylaxis treatments such as monoclonal antibody therapies, novel antivirals, and repurposed compounds.

The Government has made available a range of new treatment options within the community for National Health Service patients at greater risk from COVID-19. These treatments are licensed for use in non-hospitalised patients to reduce the risk of hospitalisation and death.

There are two ways for clinically eligible patients to access these new treatments. Those in the highest risk group from COVID-19 with a positive COVID-19 test result can access the treatments directly, following advice from a clinician at a COVID Medicines Delivery Unit. In addition, oral antiviral treatments are available through the national study, PANORAMIC, run by the University of Oxford. This study is open to clinically eligible individuals living anywhere in the UK. Further details about eligibility can be found on the PANORAMIC website in an online-only format.

Secondary information

Type

Written question

Reference

HL5824

Session

2022-23

Related items

Coronavirus: Immunosuppression
Tuesday, 11 April 2023
Written questions
House of Lords

Subjects

Disease control Coronavirus Immunosuppression

Link

View this Written question on www.parliament.uk